Literature DB >> 18415554

[Therapy for migraine-the current state of the art and perspectives.].

D Soyka1.   

Abstract

Migraine is a syndrome and not a nosological entity. It is therefore relatively improbable that a uniform etiology can be defined, and it must be assumed that there are different multifactorial etiological conditions for each individual. It is probable that a therapy concept that is equally valid and promising for all patients can therefore never be developed. On the one hand, there is a variable palette of therapeutic possibilities with a fixed differential indication with regard to the different variants of migraine, and on the other subtle analysis of individual cases is necessary by means of recording the individually relevant somatic, psychological, familial and social parameters. A treatment strategy must then be developed on an individual basis, in which both elements are taken into account. Therapy studies are carried out to investigate various questions and, accordingly, may have different experimental paradigms. The intrinsic action of a therapy method should be compared to the placebo effect on a randomized doubleblind basis. If this preconditions is fulfilled, appraisals of the real chances of success in the practice can be made more accurately on the basis of large-scale open studies comprising a representative cross-section of migraine patients. Further topics for therapy studies should include the analysis of responders and nonresponders and the development of differential indications for certain methods of therapy.

Entities:  

Year:  1987        PMID: 18415554     DOI: 10.1007/BF02527735

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  28 in total

1.  Clonidine--its use in migraine therapy.

Authors:  R E Ryan; R E Ryan
Journal:  Headache       Date:  1975-01       Impact factor: 5.887

2.  Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects.

Authors:  J R Couch; D K Ziegler; R Hassanein
Journal:  Neurology       Date:  1976-02       Impact factor: 9.910

3.  [The vasomotor headache].

Authors:  W Baust
Journal:  Med Welt       Date:  1979-05-18

4.  Migraine--treatment of acute attack.

Authors:  M Wilkinson
Journal:  Br Med J       Date:  1971-06-26

5.  [Migraine and beta blocker. An overview].

Authors:  V Pfaffenrath; W Pöllmann; G Kufner; S Drubba
Journal:  Fortschr Neurol Psychiatr       Date:  1985-01       Impact factor: 0.752

6.  Pizotifen (BC 105) in migraine prophylaxis.

Authors:  J D Carroll; W P Maclay
Journal:  Curr Med Res Opin       Date:  1975       Impact factor: 2.580

7.  Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine.

Authors:  H J Gelmers
Journal:  Headache       Date:  1983-05       Impact factor: 5.887

8.  [Migraine prevention by a calcium channel blocker. Results of a double-blind study of flunarizine vs. pizotifen].

Authors:  R Wörz; C Drillisch
Journal:  MMW Munch Med Wochenschr       Date:  1983-07-22

9.  A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine.

Authors:  P Louis
Journal:  Headache       Date:  1981-11       Impact factor: 5.887

10.  Propranolol and femoxetine, a HT-uptake inhibitor, in migraine prophylaxis. A double-blind crossover study.

Authors:  P G Andersson; E N Petersen
Journal:  Acta Neurol Scand       Date:  1981-10       Impact factor: 3.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.